Ieq Capital LLC Makes New $28.55 Million Investment in Biogen Inc. $BIIB

Ieq Capital LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 132,142 shares of the biotechnology company’s stock, valued at approximately $28,551,000. Ieq Capital LLC owned approximately 0.09% of Biogen at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Reflection Asset Management bought a new stake in shares of Biogen during the fourth quarter valued at approximately $25,000. WPG Advisers LLC raised its position in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. Bell Investment Advisors Inc acquired a new position in Biogen during the 2nd quarter worth $27,000. First Horizon Corp acquired a new position in Biogen during the 4th quarter worth $30,000. Finally, WFA of San Diego LLC bought a new position in Biogen in the 2nd quarter valued at $32,000. 87.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BIIB. Piper Sandler restated an “overweight” rating on shares of Biogen in a research report on Tuesday, July 14th. Sanford C. Bernstein lowered their price objective on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. UBS Group boosted their price objective on Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Bank of America cut their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 21st. Finally, The Goldman Sachs Group upped their target price on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $227.07.

Biogen Stock Up 1.1%

Shares of Biogen stock opened at $216.78 on Friday. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.15. The business has a 50-day moving average of $205.53 and a two-hundred day moving average of $194.48. The company has a market capitalization of $32.03 billion, a P/E ratio of 38.37, a price-to-earnings-growth ratio of 6.68 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter in the previous year, the business posted $5.47 EPS. Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.